Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

INDICATION: Pancreatic cancer

Inhibiting the translation initiator EIF4A1 and the glutamine metabolism enzyme GLS could treat pancreatic ductal adenocarcinoma (PDAC). An EIF4A1 inhibitor tool compound lowered the viability of mouse PDAC organoids and blocked glutamine metabolism in patient-derived PDAC cell lines. Treatment with a GLS inhibitor tool compound or CB-839, a GLS inhibitor from Calithera Biosciences Inc. (NASDAQ:CALA), sensitized patient-derived cells to the EIF4A1 inhibitor. The CB-839 and EIF4A1 inhibitor combination reduced tumor growth more than either agent alone in a mouse model of PDAC...